CN114931570A - Product with function of treating animal seborrheic dermatitis and application thereof - Google Patents
Product with function of treating animal seborrheic dermatitis and application thereof Download PDFInfo
- Publication number
- CN114931570A CN114931570A CN202210599987.8A CN202210599987A CN114931570A CN 114931570 A CN114931570 A CN 114931570A CN 202210599987 A CN202210599987 A CN 202210599987A CN 114931570 A CN114931570 A CN 114931570A
- Authority
- CN
- China
- Prior art keywords
- group
- unsaturated fatty
- fatty acid
- omega
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000008742 seborrheic dermatitis Diseases 0.000 title claims abstract description 62
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 title claims abstract description 61
- 241001465754 Metazoa Species 0.000 title claims abstract description 44
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims abstract description 94
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims abstract description 94
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims abstract description 38
- 239000000203 mixture Substances 0.000 claims description 58
- 235000021323 fish oil Nutrition 0.000 claims description 48
- 241000282326 Felis catus Species 0.000 claims description 20
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 14
- 235000019198 oils Nutrition 0.000 claims description 13
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 12
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 10
- 239000003921 oil Substances 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 9
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 8
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 8
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 8
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000003925 fat Substances 0.000 claims description 8
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 7
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 7
- 229960004488 linolenic acid Drugs 0.000 claims description 7
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 6
- 235000021342 arachidonic acid Nutrition 0.000 claims description 6
- 229940114079 arachidonic acid Drugs 0.000 claims description 6
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 6
- 235000019197 fats Nutrition 0.000 claims description 6
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 claims description 6
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims description 6
- 235000020664 gamma-linolenic acid Nutrition 0.000 claims description 6
- 229960002733 gamolenic acid Drugs 0.000 claims description 6
- 239000003674 animal food additive Substances 0.000 claims description 2
- 239000002537 cosmetic Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 20
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 241000700159 Rattus Species 0.000 description 79
- 210000002966 serum Anatomy 0.000 description 55
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 41
- 235000020778 linoleic acid Nutrition 0.000 description 41
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 41
- 210000003491 skin Anatomy 0.000 description 35
- 210000004209 hair Anatomy 0.000 description 28
- 210000002615 epidermis Anatomy 0.000 description 26
- 239000000047 product Substances 0.000 description 22
- 241000282472 Canis lupus familiaris Species 0.000 description 20
- 102000004388 Interleukin-4 Human genes 0.000 description 19
- 108090000978 Interleukin-4 Proteins 0.000 description 19
- 102000004889 Interleukin-6 Human genes 0.000 description 17
- 108090001005 Interleukin-6 Proteins 0.000 description 17
- 210000004207 dermis Anatomy 0.000 description 16
- 210000004919 hair shaft Anatomy 0.000 description 15
- 241000555676 Malassezia Species 0.000 description 12
- 230000005856 abnormality Effects 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 210000004969 inflammatory cell Anatomy 0.000 description 12
- 102000008186 Collagen Human genes 0.000 description 10
- 108010035532 Collagen Proteins 0.000 description 10
- 229920001436 collagen Polymers 0.000 description 10
- 239000000049 pigment Substances 0.000 description 10
- 208000017520 skin disease Diseases 0.000 description 10
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 244000005700 microbiome Species 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 230000008719 thickening Effects 0.000 description 8
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 206010015150 Erythema Diseases 0.000 description 6
- 208000003251 Pruritus Diseases 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000008595 infiltration Effects 0.000 description 6
- 238000001764 infiltration Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000000465 moulding Methods 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 210000000434 stratum corneum Anatomy 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 208000001840 Dandruff Diseases 0.000 description 5
- 208000010201 Exanthema Diseases 0.000 description 5
- 206010039509 Scab Diseases 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 201000005884 exanthem Diseases 0.000 description 5
- 210000003780 hair follicle Anatomy 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 206010037844 rash Diseases 0.000 description 5
- 238000011552 rat model Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000007803 itching Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000001732 sebaceous gland Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000282465 Canis Species 0.000 description 3
- 230000000843 anti-fungal effect Effects 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000010685 fatty oil Substances 0.000 description 3
- 230000003325 follicular Effects 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000037394 skin elasticity Effects 0.000 description 3
- 206010040882 skin lesion Diseases 0.000 description 3
- 231100000444 skin lesion Toxicity 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 206010048768 Dermatosis Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010024438 Lichenification Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000035617 depilation Effects 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 235000004626 essential fatty acids Nutrition 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 229960004125 ketoconazole Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000003934 vacuole Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 229940122739 Calcineurin inhibitor Drugs 0.000 description 1
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 description 1
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 206010059284 Epidermal necrosis Diseases 0.000 description 1
- 208000019028 Epidermal thickening Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- 102000015303 Fatty Acid Synthases Human genes 0.000 description 1
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000005775 Parakeratosis Diseases 0.000 description 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 244000007853 Sarothamnus scoparius Species 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 206010044625 Trichorrhexis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000019752 Wheat Middilings Nutrition 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 210000004430 acanthocyte Anatomy 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000037365 barrier function of the epidermis Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000005189 cardiac health Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000020930 dietary requirements Nutrition 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000000883 ear external Anatomy 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000020251 goat milk Nutrition 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 230000001329 hyperkeratotic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- 235000020939 nutritional additive Nutrition 0.000 description 1
- 206010033072 otitis externa Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229960002800 prednisolone acetate Drugs 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 244000005714 skin microbiome Species 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000021081 unsaturated fats Nutrition 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/50—Feeding-stuffs specially adapted for particular animals for rodents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Food Science & Technology (AREA)
- Animal Husbandry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a product with a function of treating animal seborrheic dermatitis and application thereof, wherein the product with the function of treating animal seborrheic dermatitis contains omega-3 unsaturated fatty acid and omega-6 unsaturated fatty acid in a specific ratio. The product with the function of treating the animal seborrheic dermatitis can effectively treat the animal seborrheic dermatitis or prevent the animal seborrheic dermatitis from happening or relapsing, has simple components, low cost and no toxic or side effect, can be widely used for treating or preventing the animal seborrheic dermatitis, and has remarkable treatment effect.
Description
Technical Field
The invention belongs to the field of veterinary medicine and nutriology, and particularly relates to a product with a function of treating animal seborrheic dermatitis and application thereof.
Background
The skin diseases refer to inflammation and injury of skin structure with different degrees under the action of different causes, and the clinical symptoms are mainly manifested by skin itch, depilation, alopecia areata, coarse hair, easy hair breakage, greasy skin, a large amount of scales on the surface of the skin, papules, pustules, crusts, ulcers, erythema, lichenification, pigment change, serous exudation, lumps and the like. Canine and feline skin disease is a pet disease which is common in clinical diseases, and epidemiological studies show that the skin disease accounts for about 42.3 percent of canine surgical diseases and 16.7 percent of feline surgical diseases by classified statistics on pet diseases. In Guangdong areas, because of climatic conditions, dogs and cats can suffer from skin diseases all the year round, the incidence rate in spring, summer and autumn is obviously higher than that in winter, wherein the incidence rate in summer is highest, and the diseases are damp and hot, particularly in the climate of 'returning to south', so that the incidence rate of the skin diseases of dogs and cats is obviously increased, the diseases are recurrent and account for about 40 percent of the total number of cases. The dermatosis of pets is caused by various fungi, bacteria, parasites, allergy, endocrine disorder and nutrient deficiency, hormone imbalance and neurogenic diseases, which are all factors that can cause the dermatosis of dogs and cats. Therefore, the canine-feline skin disease is a disease with complex etiology and easy secondary infection of various etiologies.
Seborrheic Dermatitis (SD) is a very common, chronic, and recurrent skin disease with inflammatory symptoms. Seborrheic dermatitis is clinically mainly manifested by erythema or pimple, scale and crust of skin, obvious pruritus of dogs and cats, frequent scratching actions, then greasy sebum and diffuse depilation, foul smell of putrefactive grease after development to a certain degree, redness-swelling-external otitis often accompanied, and finally pigmentation and lichenification. The incidence parts of seborrheic dermatitis are mostly located: ventral (neck, axilla, abdomen and around anus), facial (ears, nose, lips), extremities (mid-thigh and distal).
The clinical symptoms of seborrheic dermatitis are not specific, and clinical treatment mostly passes through therapeutic diagnosis, namely the symptoms of skin are relieved after antibacterial drugs are used, namely the seborrheic dermatitis is considered to be diagnosed. The main pathogenic mechanism of seborrheic dermatitis in animals is currently unclear, and only several predisposing factors of seborrheic dermatitis are determined: sebaceous gland activity, alterations in fungal (malassezia) colonization and food metabolism, host responses and individual susceptibility, epidermal barrier integrity, skin microflora, endocrine and neurological factors, and environmental changes.
In the related art, the treatment mode of animal seborrheic dermatitis is mainly antifungal treatment, for example, miconazole-chlorhexidine shampoo and 2% ketoconazole shampoo are used, or antifungal medicines such as itraconazole or ketoconazole are orally taken, but as animal seborrheic dermatitis has long course and is easy to recur, related pathogenic bacteria have already generated drug resistance to the existing treatment mode. Moreover, with the gradual increase of drug resistance, the disease course of the sick animals is prolonged, and a vicious circle is formed. The use of the steroid medicine can also relieve the itching degree of dogs and cats to a certain extent, but the itching degree can be seriously recurred again with a high probability, and the skin condition of dogs and cats cannot be thoroughly improved. There are also treatment methods using ceramide-based moisturizers, but they are milky substances and thus are not suitable for the areas with vigorous hair, such as limbs and the head. The mixed preparation containing antifungal drugs and external treatment drugs such as calcineurin inhibitor have the effects of degreasing, diminishing inflammation, sterilizing and relieving itching in principle, but the external treatment drugs are easy to repeatedly attack in actual treatment and have poor later-period curative effect. At present, the traditional Chinese medicine external treatment or local external treatment is adopted for treatment, but the treatment period is long, and the relapse situation is still serious.
Therefore, the development of a product with good treatment effect and difficult occurrence of repeated food-drug homology has great significance for inhibiting the spread and development of the animal seborrheic dermatitis, reducing the treatment cost, promoting the substitution of antibiotics and the like.
Disclosure of Invention
The present invention is directed to solving at least one of the problems of the prior art described above. Therefore, the invention provides a product with the function of treating animal seborrheic dermatitis and application thereof. The product of the invention can effectively treat animal seborrheic dermatitis or prevent the occurrence or recurrence of the seborrheic dermatitis. The product has simple components, low cost and no toxic or side effect, can be widely used for treating or preventing the seborrheic dermatitis of various animals, and has obvious treatment effect.
In a first aspect of the invention, the invention provides the application of a composition containing unsaturated fatty acid or oil containing unsaturated fatty acid in preparing a product with the function of preventing or treating animal seborrheic dermatitis.
The etiology of seborrheic dermatitis is very complex, with sebaceous gland status being a very important factor in addition to bacteria and fungi. Malassezia is a lipophilic unicellular yeast with lipase activity that hydrolyzes triglycerides in sebum to free fatty acids, while penetration of sebaceous gland secretions can lead to inflammation, irritation and increased dandruff. Although malassezia bacteria are believed in the prior art to be the major cause of seborrheic dermatitis in humans, the applicant believes that it is of greater doubt for the animal as malassezia bacteria are colonizing bacteria on the skin of healthy animals, appear lipophilic, and lack fatty acid synthase, and therefore need to rely on exogenous sources of fatty acids to meet their nutritional needs. The inventor finds through long-term experiments that the malassezia does not affect the health of the host when the skin state of the general animal host is normal; and when the skin oil secretion of the host is abnormal, the malassezia is proliferated in a large amount, and the metabolite of the malassezia contains a large amount of free fatty acid, so that the inflammatory reaction of the host is caused, and the seborrheic dermatitis is caused. Therefore, the conventional method of eliminating malassezia merely by using antibiotics or other bactericidal substances cannot effectively eradicate the occurrence of seborrheic dermatitis, but rather easily induces bacterial or fungal resistance to form a vicious circle.
In some embodiments of the present invention, the composition of the unsaturated fatty acid-containing or unsaturated fatty acid-containing fat contains an omega-3 unsaturated fatty acid and an omega-6 unsaturated fatty acid.
The omega-3 unsaturated fatty acid is one of two essential fatty acids which cannot be synthesized by human bodies and must be taken from food, and mainly comprises alpha-linolenic acid, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), wherein the fish oil is rich in a plurality of omega-3 unsaturated fatty acids such as the alpha-linolenic acid, the EPA and the DHA. The fish oil can promote the reduction of triglyceride, is beneficial to heart health and has treatment effect on various diseases of a human body, but no disclosure suggests that the fish oil can be used for treating seborrheic dermatitis.
The omega-6 unsaturated fatty acid is also an essential fatty acid which cannot be synthesized by the human body per se and must be taken from food, mainly refers to a polyunsaturated fatty acid molecule with a first double bond on the 6 th carbon atom at the omega end, and the common omega-6 unsaturated fatty acid is linoleic acid, arachidonic acid and gamma-linolenic acid, and the omega-6 unsaturated fatty acid also has no disclosure to suggest that the omega-6 unsaturated fatty acid can be used for treating the seborrheic dermatitis.
According to the requirement of malassezia on skin environment, the inventor believes that the cause of seborrheic dermatitis of pets may be more closely related to pet diet. In fact, the inventors have discovered and noted the importance of omega-6 content in the diet of animals in relation to the condition of the animal's skin. In combination with the inventors' experience in a number of studies on dietary requirements and skin disorders of pets, it was recognized that the effect of the omega-6, omega-3 proportion of fatty acids intake on seborrheic dermatitis may be much more important than prior art knowledge of the theory for malassezia actuator seborrheic dermatitis.
In some embodiments of the invention, the mass ratio of the omega-3 unsaturated fatty acid to the omega-6 unsaturated fatty acid is 1:1 to 3.
In some embodiments of the invention, the mass ratio of the omega-3 unsaturated fatty acid to the omega-6 unsaturated fatty acid is 1:1 to 2.
In some embodiments of the invention, the mass ratio of the omega-3 unsaturated fatty acid to the omega-6 unsaturated fatty acid is 1: 1.
The inventor finds out through experiments that the mass ratio of the omega-3 unsaturated fatty acid and the omega-6 unsaturated fatty acid has a larger influence on the composition for treating the seborrheic dermatitis. When the mass ratio of the omega-3 unsaturated fatty acid to the omega-6 unsaturated fatty acid is 1:4 or exceeds 1:4, the effect is relatively obviously reduced, and even when the ratio reaches 1:20, the opposite effect is generated, and the animal is induced to generate seborrheic dermatitis.
In some embodiments of the invention, the unsaturated fatty acid composition is added in an amount of 2 to 19 wt% in the product.
In some embodiments of the invention, the unsaturated fatty acid composition is added in an amount of 5 to 15 wt% in the product.
In some embodiments of the invention, the unsaturated fatty acid composition is added to the product in an amount of 8 to 12 wt%.
In some embodiments of the invention, the unsaturated fatty acid composition is added to the product at an amount of 10 wt%.
The inventor finds that the addition amount of the unsaturated fatty acid composition in related products has a large influence on the treatment of seborrheic dermatitis by the products through experiments. When the addition amount is too low (e.g., less than 1 wt%) or too high (e.g., more than 20 wt%), relatively ideal therapeutic effects cannot be produced, and seborrheic dermatitis of animals may occur even in the case where the addition amount is too different.
In some embodiments of the invention, the omega-3 unsaturated fatty acids and oils containing omega-3 unsaturated fatty acids include alpha-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid, fish oil.
Of course, those skilled in the art can select other omega-3 unsaturated fatty acids as appropriate according to the actual use requirement, including but not limited to the above-mentioned alpha-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid, and fish oil.
In some embodiments of the invention, the omega-6 unsaturated fatty acids and oils containing omega-6 unsaturated fatty acids include linoleic acid, arachidonic acid, and gamma-linolenic acid.
Of course, those skilled in the art can reasonably select other omega-6 unsaturated fatty acids according to the actual use requirements, including but not limited to the linoleic acid, arachidonic acid, and gamma-linolenic acid mentioned above.
In some embodiments of the invention, the animal comprises a rat, cat, dog.
Of course, one skilled in the art can use the composition to treat other types of animals, including but not limited to the rats, cats, and dogs, as described above, depending on the needs of the application.
In some embodiments of the invention, the product comprises a pharmaceutical, a food, a cosmetic, a feed additive.
In a second aspect of the invention, the composition contains omega-3 unsaturated fatty acid and omega-6 unsaturated fatty acid, and the mass ratio of the omega-3 unsaturated fatty acid to the omega-6 unsaturated fatty acid is 1: 1-3.
In some embodiments of the invention, the mass ratio of the omega-3 unsaturated fatty acid to the omega-6 unsaturated fatty acid is 1:1 to 2.
In some embodiments of the invention, the mass ratio of the omega-3 unsaturated fatty acid to the omega-6 unsaturated fatty acid is 1: 1.
In some embodiments of the invention, the omega-3 unsaturated fatty acids and omega-3 unsaturated fatty acid containing fats and oils include alpha-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid, fish oil.
Of course, other omega-3 unsaturated fatty acids can be reasonably selected by one skilled in the art according to actual use requirements, and include but are not limited to the alpha-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid and fish oil.
In some embodiments of the invention, the omega-6 unsaturated fatty acids and fats and oils containing omega-6 unsaturated fatty acids include linoleic acid, arachidonic acid, and gamma-linolenic acid.
Of course, those skilled in the art can reasonably select other omega-6 unsaturated fatty acids according to the actual use requirements, including but not limited to the linoleic acid, arachidonic acid, and gamma-linolenic acid mentioned above.
According to a third aspect of the invention, there is provided an animal compound feed, wherein the compound feed comprises the composition according to the second aspect of the invention, and the mass ratio of the composition to the total mass of other components in the compound feed is 2-19: 100.
In some embodiments of the invention, the mass ratio of the composition to the total mass of other ingredients in the compound feed is 5-15: 100.
In some embodiments of the invention, the mass ratio of the composition to the total mass of other ingredients in the compound feed is 8-12: 100.
In some embodiments of the invention, the mass ratio of the composition to the total mass of the other ingredients in the compound feed is 10: 100.
In some embodiments of the invention, the animal comprises a rat, cat, dog.
Of course, one skilled in the art can use the composition to treat other types of animals, including but not limited to the rats, cats, and dogs, as described above, depending on the needs of the application.
The invention has the beneficial effects that:
1. the invention provides a composition containing unsaturated fatty acid in a specific proportion, which can effectively treat seborrheic dermatitis of animals or prevent the seborrheic dermatitis from occurring or recurring, has simple components, low cost and no toxic or side effect, can be widely used for treating or preventing seborrheic dermatitis of various animals, and has obvious treatment effect.
2. The unsaturated fatty acid composition disclosed by the invention is simple in preparation method, can be prepared only by simple compounding and mixing, and has extremely good popularization significance and practical value.
Drawings
FIG. 1 is a graph comparing skin lesion scores of rats in each group.
FIG. 2 is a pathological section of rat skin in groups A-C.
FIG. 3 is the pathological section of the skin of the rats in groups D-H.
FIG. 4 is a pathological section of the skin of rats in groups I-L.
FIG. 5 is a follicular microscopic examination of rats in groups A-F.
FIG. 6 is a follicular microscopic examination of rats in groups G-L.
FIG. 7 is a graph comparing the moisture content of the skin of rats in each group.
FIG. 8 is a graph comparing the oil content in the skin of rats in each group.
FIG. 9 is a graph comparing skin elasticity indexes of rats in each group.
FIG. 10 is a graph comparing the serum IL-4 concentration in rats of each group.
FIG. 11 is a graph comparing the serum IL-6 concentration in rats of each group.
FIG. 12 is a graph comparing the serum TNF- α concentrations in rats of various groups.
FIG. 13 is a graph comparing the serum triglyceride concentration of rats in each group.
FIG. 14 is a comparison of pre-treatment and post-treatment of a diseased cat, where A is pre-treatment and B is post-treatment.
FIG. 15 is a comparison of a patient's dog before and after treatment, wherein A is before treatment and B is after treatment.
Detailed Description
In order to make the objects, technical solutions and technical effects of the present invention more apparent, the present invention will be described in further detail with reference to specific embodiments. It should be understood that the detailed description and specific examples, while indicating the preferred embodiment of the invention, are intended for purposes of illustration only and are not intended to limit the scope of the invention.
The experimental materials and reagents used are, unless otherwise specified, all consumables and reagents which are conventionally available from commercial sources.
In the following examples, the common rat feed used is an SPF-grade rat maintenance feed, which comprises the following components in percentage by mass: 33.575% of corn, 25% of flour, 17.5% of soybean meal, 13.3% of wheat middling, 4.2% of fish meal, 2.5% of soybean oil, 2% of calcium hydrophosphate (feed grade I), 1.3% of stone powder (calcium carbonate), 0.3% of salt, 0.2% of choline chloride, 0.08% of mixed mineral, 0.035% of vitamin and 0.01% of vitamin E. In the feed, the main nutrient substances account for the following components: nutrient protein 18%, carbohydrate 58%, fat 4.5%, saturated fatty acid 0.7%, monounsaturated fatty acid 1.2%, polyunsaturated fatty acid 2.6% (the total proportion of fatty acids is calculated according to 4.5%). Energy: 3.5 kcal/g. The specific nutritional composition is shown in table 1:
TABLE 1 SPF grade rat maintenance feed nutrient composition
Example 1A product with the function of treating seborrheic dermatitis in animals
In this example, the product with the function of treating seborrheic dermatitis of animals is a composition, and consists of linoleic acid and fish oil in a mass ratio of 9: 1.
The preparation method comprises the following steps: mixing the linoleic acid and the fish oil according to the proportion. The using method of the product comprises the following steps: adding into animal feed, and feeding to animals.
Example 2A product with the function of treating seborrheic dermatitis of animals
In this example, the product with the function of treating seborrheic dermatitis of animals is a composition, and consists of linoleic acid and fish oil in a mass ratio of 4: 1.
The preparation method and the using method are the same as the example 1.
Example 3A product with the function of treating seborrheic dermatitis of animals
In the embodiment, the product with the function of treating the seborrheic dermatitis of the animals is a composition, and consists of linoleic acid and fish oil in a mass ratio of 1: 1.
The preparation method and the using method are the same as the example 1.
Construction of seborrheic dermatitis rat model
In the embodiment of the invention, a seborrhoic dermatitis rat model is constructed by adding 31.5g of linoleic acid and fish oil composition into every 100g of feed, wherein the mass ratio of linoleic acid to fish oil in the linoleic acid and fish oil composition is 20: 1.
the seborrheic dermatitis rat model constructed by the method only detects that the relevant indexes and pathological states of the seborrheic dermatitis rat model constructed by the malassezia in the conventional method are completely consistent, and has longer disease maintenance time.
Effect detection of product in the above embodiment
A total of 11 different feed types were set, and the specific composition is shown in table 2. Wherein the molding feed is a composition of common rat feed and linoleic acid and fish oil in a specific proportion. The intervention feed is also a composition of common feed for rats and linoleic acid and fish oil in a specific ratio. The blank group feed is common feed for rats.
TABLE 211 composition of the different feeds
180 healthy male SD rats were randomly selected, weighing 120-160g, and divided into 12 groups (A-L) of 3 replicates per group (1-36 groups).
Wherein, the A-I groups are treatment groups (i.e. 1-27 groups, each group has 5 experimental mice, 3 parallel replicates, 9 × 5 × 3 total, and 135 total mice), after feeding 4 weeks of modeling feed to obtain seborrheic dermatitis rat model, the model is fed with different intervention feeds for 4 weeks.
Group J was a treatment control group (28-30 groups, 5 in each group, 3 in parallel, 15 in total), and after 4 weeks of model building feed to obtain a model of seborrhoeic dermatitis rats, the blank group was fed with feed for 4 weeks.
Group K was a positive control group (31-33 groups, 5 per group, 3 replicates, 15 in total), and after 4 weeks of molding feed was fed to obtain a model of seborrhoeic dermatitis rats, the molding feed was continued to be fed for 4 weeks.
Group L was a placebo group (34-36, 5 per group, 3 replicates, 15 total), and was fed 4 weeks of placebo feed for 4 weeks and then continued for 4 weeks.
The specific grouping is shown in table 3.
Table 3 feed profile for each group of rats.
Each group of rats had free diet, had free drinking water, and were raised in an environment of natural temperature, humidity and light, without restriction of activities, and after 8 weeks of feeding, each group of rats was weighed. After weighing, 3 rats in each group were randomly selected, anesthetized with ether, and then subjected to apical hemospasia of 3-4mL, with the blood sample to be tested. Then, a sterile cotton swab is used for dipping sterile normal saline, the root of the hair of the rat is rubbed to collect dander, and a sample is reserved for detecting the content of the malassezia caused by skin infection. The skin tissue of the lesion part is cut off by an alcohol-sterilized operation, and is preserved by 4 percent paraformaldehyde universal tissue fixing solution, and the sample is reserved for detecting the condition of the skin tissue. All sera and samples were stored in a-80 ℃ freezer.
(1) Skin damage scoring:
the clinical appearance scores were used to score the appearance of different groups of rats, and the sites to be observed were: the nape (the area from the top of the head to the tail); ear root and perioral region; the healed part after the abrasive paper is worn; the root of the limbs has less hair. The appearance was scored according to the predominant manifestations of seborrheic dermatitis symptoms (redness, swelling, greasiness, scaling, alopecia).
The scoring range of each skin damage degree is 0-3 points: score 0 indicates no overt symptoms; score 1 indicates mild lesions; score 2 indicates moderate lesion; and 3, dividing into severe lesions.
Specific scoring criteria are shown in table 4.
TABLE 4 clinical appearance scoring standard for seborrhoeic dermatitis experimental animals
The total score is the comprehensive score of all the items, the total score is 9 points, and the total score is more than or equal to 5 points, the molding is considered to be successful. Treatment is deemed to be achieved if the total score after treatment is less than or equal to 5.
The results of the skin lesion scoring are shown in table 5 and fig. 1.
TABLE 5 evaluation results of skin lesions of experimental rat
| Grouping | Hair removal | Erythema | Scale and chip | Total score of |
| A | 1.86 | 0.86 | 0.40 | 5.50 |
| B | 1.73 | 0.93 | 1.87 | 6.40 |
| C | 1.80 | 0.20 | 3.00 | 5.93 |
| D | 1.79 | 0.93 | 2.64 | 6.64 |
| E | 2.53 | 1.07 | 2.60 | 6.00 |
| F | 1.40 | 0.07 | 2.53 | 3.73 |
| G | 1.47 | 0.27 | 2.93 | 5.00 |
| H | 1.14 | 0.71 | 3.00 | 3.86 |
| I | 1.46 | 0.46 | 2.77 | 4.54 |
| J | 2.07 | 0.73 | 2.53 | 5.80 |
| K | 2.14 | 0.86 | 1.64 | 5.86 |
| L | 1.07 | 0.94 | 0.69 | 1.53 |
It can be found that treatment scores higher than 5 are group a (5.50), group B (6.40), group C (5.93), group D (6.64), group G (5.00), group J (5.80), group K (5.86); the remaining treatment scores in groups F (3.73), H (3.86), I (4.54), and L (1.53) were all less than 5 points on average. The rest L groups are used as blank control groups in the molding stage and the treatment stage, after the treatment of the last 4 weeks, the scores have no significant difference with the scores in the molding stage and are all kept at about 2, and the result is proved to be effective. In each experimental group, the treatment effect of the group F (linoleic acid: fish oil is 1:1, and the addition amount of the fish oil linoleic acid composition is 10% of the feed) is the worst, the treatment effect of the group D (linoleic acid: fish oil is 9:1, and the addition amount of the fish oil linoleic acid composition is 10% of the feed) is the worst, and the treatment effect of the group F (linoleic acid: fish oil is 1:1, and the addition amount of the fish oil linoleic acid composition is 10% of the feed) is the best, except for the blank group.
(2) Preparing a skin pathological section:
after the skin tissue sample is soaked in the fixing solution for 24 hours, the periphery of the skin tissue sample is trimmed by a scalpel, and then the skin tissue sample is placed in a dewatering box and washed overnight by running water. Then dehydrated, clarified and waxed (using different concentrations of alcohol, xylene and paraffin, according to the usual procedures in the art). After embedding, slicing, spreading, fishing, baking and dewaxing are carried out. Staining with hematoxylin staining solution for 3-5 min. Then placing the dehydrated mixture into eosin dye solution for dyeing for 5 min. After re-dehydration a clear neutral gum seal was used. And (5) microscopic examination.
The results are shown in FIGS. 2 to 4 and Table 6.
It can be seen that the results in group a show that the epidermis is intact, mild thickening of the epidermis is widely seen (black arrows), the morphology of epidermal cells is normal, the stratum corneum is locally and lightly hyperkeratotic (red arrows), edema in a small range of the dermis, collagen is loose (yellow arrows), a small amount of inflammatory cells are scattered in the dermis to infiltrate (green arrows), and no other obvious abnormalities are seen. The results in group B showed extensive mid-to-severe thickening of the epidermis, local excoriation (black arrows), with a small range of necrosis of the epidermis (red arrows) and exudation of more inflammatory substances (yellow arrows), a large amount of inflammatory substances exuded outside the epidermis, and a small purple powder mass, considered as a bacterial mass (green arrows), more vacuolated epidermal cells (blue arrows), several abscess foci outside the epidermis, and a small amount of inflammatory cells scattered in the dermis layer to infiltrate. The results in group C showed complete epidermis, local mild to moderate thickening (black arrows), abundant collagen in the dermis, small numbers of inflammatory cells scattered in the dermis (red arrows) in the small range, and no other obvious abnormalities. The results in group D showed extensive mild to moderate thickening of the epidermis (black arrows), occasional necrosis of the epidermis, with a small infiltration of pus cells, a large exudation of inflammatory substances outside the local epidermis (red arrows), a small vacuolation of the cytoplasm of the epithelial cells (yellow arrows), a small scattering of inflammatory cells in the dermis (green arrows), and no other apparent abnormalities. The results in group E show a small range of epidermal necrosis, involvement of the superficial dermis, with a small amount of inflammatory cell infiltration (black arrow), a small amount of epidermal thickening (red arrow), with a small amount of epithelial cell cytoplasmic vacuolization (yellow arrow), a greater inflammatory substance exudation visible in the local epidermis (green arrow), and a small amount of inflammatory cells scattered in the dermis in infiltration (blue arrow), with a small amount of capillary dilation (orange arrow). The results in group F showed that the epidermis was intact, mild thickening of the epidermis (black arrows) was observed extensively, the dermis was rich in collagen, a small amount of inflammatory cells scattered in the infiltrate (red arrows) were observed, and no other obvious abnormalities were observed. The results in group G show intact epidermis, mild local thickening of epidermis (black arrows), abundant collagen in dermis, little inflammatory cell infiltration (red arrows), reduced collagen in dermis, fibrocyte proliferation in small areas, and no other obvious abnormalities. The results in group H show that the epidermis is intact, mild thickening of the epidermis is widely seen (black arrows), the dermis is rich in collagen, a small amount of inflammatory cells are scattered in the infiltrate (red arrows), and no other obvious abnormalities are seen. The results in group I show that the epidermis is intact, mild thickening of the epidermis is widely seen (black arrows), the dermis is rich in collagen, a small amount of inflammatory cells are scattered in the infiltration (red arrows), and no other obvious abnormality is seen. The results in group J show that the epidermis is intact, the epidermis is widely seen to be slightly to moderately thickened (black arrows), the stratum corneum is seen to have a plurality of abscesses (red arrows), the stratum corneum is seen to be parakeratosis, residual cell nuclei (yellow arrows) are seen, the dermis is rich in collagen, more inflammatory cells are scattered to infiltrate (green arrows), and other obvious abnormalities are not seen. The results in group K show that the epidermis is intact, the small area of the epidermis is slightly to moderately thickened (black arrows), with a small amount of plasma vacuolization of epithelial cells (red arrows), the stratum corneum is occasionally abscessed (yellow arrows), the dermis is rich in collagen, a small amount of inflammatory cell infiltration is locally seen (green arrows), small blister formation is seen below the epidermis (blue arrows), and no other obvious abnormalities are seen. The L groups have complete epidermis, uniform thickness of the epidermis and clear layers, and can see stratum corneum, granular layers, acanthocyte layers and basal layers, the dermis layer has rich collagen and compact arrangement, more hair follicles and sebaceous glands can be seen, the shape is normal, and the tissues have no obvious abnormality.
Table 6 pathological section results of rat skin
(3) Performing follicular microscopy:
the whole hair (including hair follicle) around the diseased skin of a plurality of roots is drawn, and the hair shaft abnormality and trichophyton abnormality are detected after sample retention.
The results are shown in FIGS. 5 to 6 and Table 7.
The hair shaft cuticle of the group A is damaged, swelled, rough, uneven distribution of hair marrow pigments and broken, and the hair is indicated to be dysplastic; the hair follicle in the group B is dysplastic, the hair shaft has uneven cuticle structure and uniform pigment distribution; c group hair shafts are attached with scurf and spherical microorganisms, the cuticle is incomplete, the hair pith has vacuole structures, and pigments are invisible; d, attaching microorganisms to hair follicles, breaking hair roots, uneven broken ends in broom shape, attaching dander to hair shafts, and unevenly distributing spherical microorganisms and pigments; group E hair shaft cuticle damage, swelling, microorganism invasion into hair shaft medulla layer, and hair shaft deformation; the hair shaft stratum corneum of the F group is uneven in structure, expands and adheres to microorganisms, hair pith pigment is distributed unevenly, and fracture occurs; group G hair shafts are attached with scurf and spherical microorganisms, the cuticle is incomplete, and hair marrow pigments are unevenly distributed and are broken; the hair shaft attachment scurf block mass in the H group is complete in cuticle, uniform in hair pith pigment distribution, and relatively normal in the whole hair state; the hair shafts of the group I are attached with microorganism lumps, the hair is thin, the cuticle and the marrow layer are not obvious, and the whole hair state is dysplastic; group J hair shaft attachment scurf and spherical microorganism, incomplete cuticle, vacuole structure of hair marrow, and disappearance of pigment; the K groups of horny layers are damaged, expanded and unevenly distributed; the hair shaft of the L group of hair has complete structure, smooth cuticle and uniform hair marrow pigment distribution. From the above results, the therapeutic effect was best in the group H (linoleic acid: fish oil: 4:1, and the amount of fish oil linoleic acid composition added was 1% of the feed) relative to the other experimental groups.
TABLE 7 detection results of hair shaft, hair follicle and hair marrow of rats in each group
(4) Skin condition examination:
on the last day of the experiment, rats were randomly drawn from each group and skin moisture, skin oil content and elasticity index were measured with a skin measuring instrument.
The results are shown in FIGS. 7 to 9.
It can be found that the skin moisture content of rats in different groups after treatment sequentially changes from low to high in group C (24.64%), group L (25.53%), group I (25.77%), group F (26.13%), group K (26.29%) J (26.40%), group G (26.60%), group B (27.70%), group D (27.20%), group E (27.73%) and group H (27.93%) group a (28.53%), and there is no significant difference between groups (P > 0.05).
After treatment, the average skin oil content of rats in the group C is 51.47% at the lowest, the rest groups comprise blank groups, the average skin oil content of the rats is similar, and no obvious difference exists between 54% and 55%.
After treatment, the average skin elasticity index of rats in the group A is 46.73 at the highest, the other groups comprise blank groups, the average skin elasticity indexes of the rats are similar and have no obvious difference between 44.07 and 45.80.
In conclusion, at the end of the treatment period, the skin moisture, oil and elasticity indexes of the rats have no obvious difference
(5) And (3) detecting cytokines:
collecting blood samples of rats of each group, standing at room temperature for 10-20min, centrifuging at 2000rp/min for 20min, collecting supernatant, and storing at-2 ℃ for cytokine detection.
Interleukin 4(IL-4), interleukin 6(IL-6) and tumor necrosis factor (TNF-alpha) in the serum sample were detected by using commercially available detection kits, respectively. Meanwhile, the content of triglyceride in the serum sample is detected by using a serum triglyceride detection kit.
The results are shown in FIGS. 10 to 13 and Table 8.
TABLE 8 serum factor test results of different groups of rats
Analyzing the relation between the concentration of serum factors and the proportion, the content and the combined action of the content-proportion of two unsaturated fatty acids by using multifactorial variance, and finding that the concentrations of IL-4, IL-6 and TNF-alpha in serum are related to the contents of the ingested omega-3 unsaturated fatty acid and omega-6 unsaturated fatty acid (P <0.05), and the concentration of TG is not related to the contents of the ingested omega-3 unsaturated fatty acid and omega-6 unsaturated fatty acid (P > 0.05); the concentration of IL-4 and TNF-alpha in serum has no correlation with the ratio of the ingested omega-3 unsaturated fatty acid and the ingested omega-6 unsaturated fatty acid (P is more than 0.05), and the concentration of IL-6 and TG in serum has obvious correlation with the ratio of the ingested omega-3 unsaturated fatty acid and the ingested omega-6 unsaturated fatty acid (P is more than 0.05); the IL-4 concentration in serum has a correlation with the content-ratio combined action of the ingested omega-3 unsaturated fatty acid and omega-6 unsaturated fatty acid (P <0.05), and the content-ratio combined action of the ingested omega-3 unsaturated fatty acid and omega-6 unsaturated fatty acid has no correlation with the IL-6, TNF-alpha and TG concentrations (P > 0.05).
FIG. 10 is a graph comparing the serum IL-4 concentration in rats of each group. It was found that from the analysis of the content of omega-3 unsaturated fatty acids and omega-6 unsaturated fatty acids, the IL-4 concentration in the serum of rats was higher (P <0.05) in the building block (group K), in the experimental groups (group A, group B, group C) supplemented with 20% fish oil linoleic acid composition and in the experimental groups (group D, group E, group F) supplemented with 10% fish oil linoleic acid composition, compared to the blank group (group L) rats; the IL-4 concentration in serum of rats in group J was significantly higher than that of experimental groups (group G, group H, group I) to which 1% fish oil linoleic acid composition was added (P < 0.05). The model building group (group K) rat serum IL-4 concentrations were significantly lower than the experimental group and the L group (blank) to which 1% fish oil linoleic acid composition was added (P < 0.05). Comparison of experimental groups with three different levels (1%, 10%, 20%) of fish oil linoleic acid composition showed: the IL-4 concentration of the serum of rats in the experimental group added with 1 percent is lower than that in other experimental groups (P < 0.05); the IL-4 concentration in the serum of rats in the experimental group with 20% of the additive and the experimental group with 10% of the additive has no significant difference (P > 0.05).
And from the content-ratio combined action analysis of the omega-3 unsaturated fatty acid and the omega-6 unsaturated fatty acid, the results show that: the highest IL-4 concentration (219.83ng/L) in the serum of the rats in the E group; the lowest IL-4 concentration (160.48ng/L) in the serum of the rats in the H group; the IL-4 concentration in serum of group J rats (182.06ng/L) was lower than that of the blank group (group L, 205.25ng/L) and the model group (group K, 199.10 ng/L).
FIG. 11 is a graph comparing the serum IL-6 concentration in rats of each group. It can be found that from the content analysis of omega-3 unsaturated fatty acid and omega-6 unsaturated fatty acid, the IL-6 concentration in the serum of the rats in the blank group (L group) has no significant difference (P >0.05) with the rats in other experimental groups; the IL-6 concentration in the serum of the model-building rats (group K) is higher than that of the experimental groups (group G, group H and group I) added with 1% fish oil linoleic acid composition; the IL-6 concentration in the serum of the rats in the J group has no significant difference with the rats in other experimental groups (P > 0.05). Comparison of experimental groups with three different levels (1%, 10%, 20%) of fish oil linoleic acid composition showed: the highest IL-6 concentration in the serum added with 10 percent of experimental groups (D group, E group and F group); the IL-6 concentration was lowest in the serum added to 1% of the experimental groups (group A, group B, and group C). From the ratio analysis of omega-3 unsaturated fatty acid and omega-6 unsaturated fatty acid, the IL-6 concentration in the serum of the rats in the blank group (L group) and the J group has no significant difference with other experimental groups; the IL-6 concentration in the serum of the model building rats (group K) is obviously higher than that of the serum added with fish oil linoleic acid in a ratio of 1: experimental group of 1 (group C, group F, group I) (P < 0.05).
Comparison of the experimental groups with three different fish oil to linoleic acid ratios (1: 1, 4:1, 9: 1) shows: the adding proportion is 1: the concentration of IL-6 in serum of the experimental group (group C, group F and group I) of 1 is obviously lower than that of the serum added according to the proportion of 9:1 (group a, group D, group G) (P <0.05) and the ratio of addition to the test group (group a, group D, group G) was 4: the experimental groups of 1 (group B, group E, group H) had no significant difference (P > 0.05); the adding proportion is 4:1 (group B, group E, group H) serum IL-6 concentration to addition ratio was 9: the experimental groups of 1 (group a, group D, group G) were not significantly different (P > 0.05). Wherein, the IL-6 concentration in the serum of the rats in the E group is the highest (219.83ng/L) in combination; the lowest IL-4 concentration in H rat serum (160.48 ng/L); the IL-4 concentration in serum of group J rats (182.06ng/L) was lower than that of the rats of the blank group (group L, 205.25ng/L) and the model group (group K, 199.11 ng/L).
FIG. 12 is a graph comparing the serum TNF- α concentrations in rats of various groups. It was found from the content analysis of the omega-3 unsaturated fatty acid and the omega-6 unsaturated fatty acid that the TNF-alpha concentration in the serum of the rats in the blank group (group L) was higher than that in the experimental groups (group a, group B, group C) to which the 20% fish oil linoleic acid composition was added, that in the experimental groups (group D, group E, group F) to which the 10% fish oil linoleic acid composition was added, and that in the group J (P <0.05), there was no significant difference (P >0.05) between the building group (group K) and the experimental groups (group G, group H, group I) to which the 1% fish oil linoleic acid composition was added. The serum TNF- α concentration in rats in group J was lower than that in the model group (group K) and in the experimental groups (group G, group H, group I) to which 1% of TNF- α was added (P < 0.05). The TNF-alpha concentration in the serum of the model group (group K) is lower than that of the experimental group (P <0.05) added with 20 percent (group A, group B and group C) and 10 percent (group D, group E and group F) and has no obvious difference (P >0.05) from other experimental groups. Comparison of experimental groups with three different levels (1%, 10%, 20%) of fish oil linoleic acid composition showed: the concentration of TNF-alpha in the serum of rats added with 1 percent of the experimental groups (A group, B group and C group) is obviously higher than that of rats added with 20 percent (G group, H group and I group) and 10 percent (D group, E group and F group) (P < 0.05); there was no significant difference between the serum TNF- α concentrations in the rats in the 20% and 10% addition groups (P > 0.05).
In combination, group H serum TNF- α was at the highest concentration (1303.76ng/L), group A serum TNF- α was at the lowest concentration (778.56ng/L), and IL-4 was lower in the serum of the model group (group K, 789.29ng/L) than in the serum of the blank group (group L, 1154.22ng/L) and group J rats (1287.74 ng/L).
FIG. 13 is a graph comparing the serum triglyceride concentration of rats in each group. It can be found that from the ratio analysis of the omega-3 unsaturated fatty acid and the omega-6 unsaturated fatty acid, the serum TG concentration of the rats in the blank group (group L) and the J group and the model group (group K) has significant difference (P <0.05) and has no significant difference (P >0.05) with other experimental groups; the difference of TG concentration in the serum of the rats in the J group is not obviously different from that of a model building group (the K group), and is obviously different from that of other experimental groups (P < 0.05); the building blocks (group K) were significantly different from all experimental groups except group J (P < 0.05). Comparison of experimental groups with three different levels (1%, 10%, 20%) of fish oil linoleic acid composition showed: the adding proportion is 1:1 (group C, group F, group I) the TG concentration in the rat serum was significantly higher than the addition ratio of 4:1 (group B, group E, group H) (P <0.05) in a ratio of 9: the experimental groups of 1 (group a, group D, group G) were not significantly different; the adding proportion is 4:1 (group B, group E, group H) the TG concentration in the rat serum was significantly lower than the addition ratio of 9: experimental group of 1 (group a, group D, group G) (P < 0.05).
In combination, group G had the highest serum TG concentration (1.45mmo/L), group B had the lowest serum TNF- α concentration (0.75134mmo/L), and the serum IL-4 concentration of the model group (group K, 1.15mmo/L) was higher than that of the rats of the blank group (group L, 0.75ng/L) and group J (1.97 mmo/L).
Actual therapeutic efficacy of Fish oil linoleic acid compositions
To fully demonstrate the linoleic acid mentioned above: the fish oil linoleic acid composition with a ratio of fish oil of about 1:1 and a content of about 10% does have a good therapeutic effect on seborrhea in animals, and the inventor uses it in actual clinical treatment and randomly draws each of dogs and cats as an example to be explained here. Of course, it should be understood by those skilled in the art that the following cases are used as examples only and are not limiting to the embodiments of the present invention.
(1) Clinical cases of cats:
male Jiafei cat, 4 years old, is fed indoors, and is fed with complete adult cat food as main material, canned food and freeze-dried food as auxiliary materials. After 4 months, the owner found that the cat had frequent scratching movements, had rough hair, had greasy feel to the skin, had red rash after one week, and was diagnosed with seborrheic dermatitis.
The treatment content is as follows: shaving off hair of the diseased region, carrying out medicated bath soaking once a week, and adding the linoleic acid: a fish oil linoleic acid composition in a ratio of about 1:1 and in an amount of about 10%.
The treatment results are as follows: after two weeks of treatment, the cat erythema disappears, the new hair is smooth and soft, the greasy skin feel disappears and the itching feel disappears. Follow-up survey, the pet owner reflects that the cats continue to eat the feed containing the linoleic acid: the pet food of the fish oil linoleic acid composition with the fish oil ratio of about 1:1 and the content of about 10 percent is taken as a nutritional additive, the eating times are reduced to once a day, no adverse reaction is caused, no allergic symptoms occur, new hair grows at the unhairing position, and no seborrheic dermatitis relapse occurs.
A comparison of the pre-and post-treatment profiles for cats is shown in FIG. 14.
(2) Clinical cases of dogs:
frontier shepherd dogs, male, 4-month-old, were stocked outdoors, and were fed on a weekday with puppy food as the primary and raw bones, jerky, goat milk as the secondary. After 3 months, the master finds that the dog has obvious red rash on the nose and the armpit and is accompanied with otitis. The master shows that the dog is bathed at home one week before the dog has hair completely dried, and the red rash and blood scab appear on the armpit of the dog five days later, the nose and the head appear in succession, and finally the external ear is red and swollen. It is diagnosed as seborrheic dermatitis.
The treatment content is as follows: according to the feed intake of dogs, the linoleic acid: a fish oil linoleic acid composition in a ratio of fish oil of about 1:1 and in an amount of about 10%; carrying out medicated bath soaking for two times; taking prednisolone acetate 1 tablet/day; the ear can wash the ear liquid in the ear.
The treatment results are as follows: after 10 days of treatment, the canine nose red rash disappears, the oxter blood scab falls off, the red rash is reduced, and the ear red swelling disappears. Follow-up survey shows that pet owners can continuously eat pet food containing the fish oil linoleic acid composition after recovery, no adverse reaction is caused, no anaphylactic symptom is caused, hair is glossy and bright, newly born hair grows on affected parts with hair loss and blood scabs, the state of the newly born hair is reflected to be healthy after examination of pet hospitals, and no seborrheic dermatitis relapse occurs.
A comparative plot before and after treatment of the affected dogs is shown in figure 15.
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such modifications are intended to be included in the scope of the present invention.
Claims (10)
1. Application of a composition containing unsaturated fatty acid or unsaturated fatty acid-containing oil in preparing product with animal seborrheic dermatitis preventing or treating function is provided.
2. The use according to claim 1, wherein the composition containing an unsaturated fatty acid or an unsaturated fatty acid-containing fat contains an omega-3 unsaturated fatty acid and an omega-6 unsaturated fatty acid.
3. The use according to claim 2, wherein the mass ratio of the omega-3 unsaturated fatty acid to the omega-6 unsaturated fatty acid is 1:1 to 3.
4. The use according to claim 1, wherein the unsaturated fatty acid or unsaturated fatty acid oil-and-fat-containing composition is added in an amount of 2-19 wt% in the product.
5. Use according to claim 2 or 3, wherein the omega-3 unsaturated fatty acids or omega-3 unsaturated fatty acid containing fats and oils comprise alpha-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid, fish oil.
6. Use according to claim 2 or 3, wherein the omega-6 unsaturated fatty acid or omega-6 unsaturated fatty acid containing fat comprises linoleic acid, arachidonic acid, gamma-linolenic acid.
7. The use of claim 1, wherein the animal comprises a rat, cat, or dog.
8. Use according to claim 1, wherein the product comprises a pharmaceutical product, a food product, a cosmetic product, a feed additive.
9. The composition is characterized by comprising omega-3 unsaturated fatty acid and omega-6 unsaturated fatty acid, wherein the mass ratio of the omega-3 unsaturated fatty acid to the omega-6 unsaturated fatty acid is 1: 1-3.
10. An animal compound feed, characterized in that the compound feed contains the composition of claim 9, and the mass ratio of the composition to the total mass of other components in the compound feed is 2-19: 100.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210599987.8A CN114931570A (en) | 2022-05-30 | 2022-05-30 | Product with function of treating animal seborrheic dermatitis and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210599987.8A CN114931570A (en) | 2022-05-30 | 2022-05-30 | Product with function of treating animal seborrheic dermatitis and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114931570A true CN114931570A (en) | 2022-08-23 |
Family
ID=82866765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210599987.8A Pending CN114931570A (en) | 2022-05-30 | 2022-05-30 | Product with function of treating animal seborrheic dermatitis and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114931570A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1264670A (en) * | 1984-08-15 | 1990-01-23 | David Frederick Horrobin | Treatment of skin disorders |
| JP2005522204A (en) * | 2002-04-12 | 2005-07-28 | ザ・アイムス・カンパニー | How to improve canine performance by diet |
| CN101596318A (en) * | 2008-06-04 | 2009-12-09 | 北京普润生物科技发展有限公司 | The external preparation of treatment androgens psilosis and seborrheic dermatitis, acne |
| CN104994911A (en) * | 2012-09-06 | 2015-10-21 | 尊贵科学有限公司 | Cosmetic compositions comprising epa and gla and methods of making and using same |
| CN106490190A (en) * | 2015-09-08 | 2017-03-15 | 中粮食品营销有限公司 | A kind of edible blend oil |
-
2022
- 2022-05-30 CN CN202210599987.8A patent/CN114931570A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1264670A (en) * | 1984-08-15 | 1990-01-23 | David Frederick Horrobin | Treatment of skin disorders |
| JP2005522204A (en) * | 2002-04-12 | 2005-07-28 | ザ・アイムス・カンパニー | How to improve canine performance by diet |
| CN101596318A (en) * | 2008-06-04 | 2009-12-09 | 北京普润生物科技发展有限公司 | The external preparation of treatment androgens psilosis and seborrheic dermatitis, acne |
| CN104994911A (en) * | 2012-09-06 | 2015-10-21 | 尊贵科学有限公司 | Cosmetic compositions comprising epa and gla and methods of making and using same |
| CN106490190A (en) * | 2015-09-08 | 2017-03-15 | 中粮食品营销有限公司 | A kind of edible blend oil |
Non-Patent Citations (1)
| Title |
|---|
| 李向党: "脂肪酸在犬营养上的地位", 《中国工作犬业》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2718919C1 (en) | Composition for treating acne | |
| CN113599319B (en) | Multi-effect nursing cosmetic composition for infants | |
| CN107019655B (en) | Oil control composition and application thereof | |
| CN109431914B (en) | Scalp care composition and application thereof | |
| CN105411960A (en) | Mask with acne inhibition effect and preparation method thereof | |
| CN110169926A (en) | The preparation process of the natural composition and its cream of efficiently anti-inflammatory, prevention and treatment infantile eczema and enhancing barrier function | |
| Badiu et al. | Effect of olive oil on the skin | |
| KR20130088997A (en) | Cosmetic composition for hair growth and restoration from caviar extracts and its fermentation | |
| CN110638727A (en) | Infant hip-protecting composition and preparation method and application thereof | |
| CN110302121B (en) | Infant hip-protecting cream containing plant essence and preparation method thereof | |
| WO2020022131A1 (en) | Anti-aging agent for skin and anti-aging-related gene expression regulator | |
| CN108295022B (en) | Acne-removing composition and preparation method thereof | |
| CN111728913B (en) | Polypeptide acne-removing composition and preparation method and application thereof | |
| KR101835799B1 (en) | A cosmetic composition for manufacturing by the using of propolis, and the cosmetic manufactured by the composition | |
| CN114931570A (en) | Product with function of treating animal seborrheic dermatitis and application thereof | |
| CN112807238A (en) | Anti-inflammatory and soothing repair gel for skin and preparation method thereof | |
| Kleczkowski et al. | Usefulness of clinical, histopathological and some biochemical and mineral investigations in diagnosis of bovine hyperkeratosis in dairy cattle | |
| CN110801406A (en) | Multi-effect facial mask repairing liquid and preparation method thereof | |
| US11666622B2 (en) | Topical treatment for animals | |
| RU2142783C1 (en) | Regenerative cosmetic means for skin care | |
| CN116869855B (en) | Skin care composition containing collagen | |
| CN113577205B (en) | Composite skin nutrition composition and preparation method and application thereof | |
| EP3310351B1 (en) | Oral use of zinc- and copper gluconates in the treatment of digital dermatitis | |
| CN114946756A (en) | Construction method and application of seborrheic dermatitis animal model | |
| Binek et al. | Mirosław Kleczkowski1, Włodzimierz Kluciński1, Marian Binek2, Mikołaj Gralak3, Iwona Badurek1, Magdalena Garncarz1, Marek Kulka1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220823 |